Thursday, November 30, 2006

Third Wave Announces Launch of Universal Invader(R) Program

Third Wave Announces Launch of Universal Invader(R) Program

Stocks mentioned in this article
Third Wave Technologies, Inc. (TWTI) Stock Quote, Chart, News

ORLANDO, Fla.,-- Third Wave Technologies Inc. TWTI today announced the launch of its Universal Invader(R) Program, which allows customers to design, build and optimize their own Invader(R) chemistry-based assays.

"Third Wave is pleased to open access to our Invader(R) chemistry, making an already simple, flexible chemistry even easier for customers to use," said Kevin T. Conroy, president and chief executive of Third Wave. "The Universal Invader(R) Program enables Third Wave to better serve our customers by providing them the flexibility to develop tests that meet their specific needs and interests, outside of our standard menu of products."

The program includes web-based Universal Invader(R) design software. The software generates the designs for all oligonucleotides, or DNA probes, needed for customers to build Invader(R) chemistry-based reactions for their specific DNA targets of interest in their own laboratories. Participants in the Universal Invader(R) Program can purchase their design-specific oligonucleotides from a third-party vendor and general purpose reagents, including Third Wave's Cleavase(R) enzyme, directly from the company.

The program utilizes the Third Wave's Invader Plus(R) chemistry, which combines the accuracy and specificity of its Invader(R) chemistry with the sensitivity of PCR sample amplification. Customers can use the Invader Plus(R) chemistry without paying any royalty because the relevant PCR patents expired last year. For more information about the Universal Invader(R) Program, please visit .

About Third Wave Technologies

Third Wave develops and markets molecular diagnostic reagents for a variety of DNA and RNA analysis applications to meet the needs of our customers. The company offers a number of products based on its Invader(R) chemistry for clinical testing. Third Wave offers in vitro diagnostic kits, and analyte specific, general purpose, and research use only reagents for nucleic acid analysis. For more information about Third Wave and its products, please visit the company's website at .

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for Third Wave from those projected. Those factors include risks and uncertainties relating to technological approaches of Third Wave and its competitors, product development, manufacturing, market acceptance, cost and pricing of Third Wave products, dependence on collaborative partners and commercial customers, successful performance under collaborative and commercial agreements, competition, the strength of the Third Wave intellectual property, the intellectual property of others and other risk factors identified in the documents Third Wave has filed, or will file, with the Securities and Exchange Commission. Copies of the Third Wave filings with the SEC may be obtained from the SEC Internet site at . Third Wave expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Third Wave's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Third Wave Technologies, Invader and the Third Wave logo are trademarks of Third Wave Technologies, Inc.

No comments: